X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STRIDES SHASUN LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STRIDES SHASUN LTD IPCA LABS/
STRIDES SHASUN LTD
 
P/E (TTM) x 44.6 13.2 337.6% View Chart
P/BV x 3.4 1.5 223.4% View Chart
Dividend Yield % 0.2 0.6 23.2%  

Financials

 IPCA LABS   STRIDES SHASUN LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
STRIDES SHASUN LTD
Mar-17
IPCA LABS/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs6431,275 50.4%   
Low Rs503918 54.8%   
Sales per share (Unadj.) Rs254.4389.6 65.3%  
Earnings per share (Unadj.) Rs16.128.0 57.5%  
Cash flow per share (Unadj.) Rs29.848.9 60.9%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.20.4 42.5%  
Book value per share (Unadj.) Rs194.6303.1 64.2%  
Shares outstanding (eoy) m126.2089.42 141.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.32.8 80.0%   
Avg P/E ratio x35.739.2 90.9%  
P/CF ratio (eoy) x19.222.4 85.8%  
Price / Book Value ratio x2.93.6 81.4%  
Dividend payout %6.216.1 38.7%   
Avg Mkt Cap Rs m72,30098,036 73.7%   
No. of employees `00013.35.8 229.4%   
Total wages/salary Rs m6,9605,881 118.3%   
Avg. sales/employee Rs Th2,413.56,005.9 40.2%   
Avg. wages/employee Rs Th523.21,014.0 51.6%   
Avg. net profit/employee Rs Th152.4431.2 35.4%   
INCOME DATA
Net Sales Rs m32,10634,834 92.2%  
Other income Rs m2261,686 13.4%   
Total revenues Rs m32,33236,520 88.5%   
Gross profit Rs m4,4486,428 69.2%  
Depreciation Rs m1,7301,872 92.4%   
Interest Rs m2412,269 10.6%   
Profit before tax Rs m2,7033,973 68.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m675470 143.7%   
Profit after tax Rs m2,0282,501 81.1%  
Gross profit margin %13.918.5 75.1%  
Effective tax rate %25.011.8 211.1%   
Net profit margin %6.37.2 88.0%  
BALANCE SHEET DATA
Current assets Rs m17,34038,165 45.4%   
Current liabilities Rs m9,55930,402 31.4%   
Net working cap to sales %24.222.3 108.7%  
Current ratio x1.81.3 144.5%  
Inventory Days Days10077 129.7%  
Debtors Days Days57104 54.4%  
Net fixed assets Rs m20,77937,639 55.2%   
Share capital Rs m252894 28.2%   
"Free" reserves Rs m24,49926,210 93.5%   
Net worth Rs m24,55327,105 90.6%   
Long term debt Rs m3,51716,377 21.5%   
Total assets Rs m39,59581,168 48.8%  
Interest coverage x12.22.8 444.5%   
Debt to equity ratio x0.10.6 23.7%  
Sales to assets ratio x0.80.4 188.9%   
Return on assets %5.75.9 97.5%  
Return on equity %8.39.2 89.5%  
Return on capital %10.512.1 87.0%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61713,465 116.0%   
Fx outflow Rs m5,8284,076 143.0%   
Net fx Rs m9,7909,389 104.3%   
CASH FLOW
From Operations Rs m2,7642,881 95.9%  
From Investments Rs m-1,432-7,051 20.3%  
From Financial Activity Rs m-1,5913,382 -47.0%  
Net Cashflow Rs m-259-788 32.9%  

Share Holding

Indian Promoters % 45.9 27.7 165.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 37.8 30.2%  
FIIs % 25.3 8.6 294.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 25.9 67.2%  
Shareholders   36,892 56,241 65.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 22, 2018 02:07 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS